

1 **Full title:**

2 Smallpox bioterrorism scenarios and reactive intervention protocol: mathematical model-based
3 analysis

4

5 **Short title:**

6 Mathematical model-based analysis of smallpox bioterrorism

7

8 **Author list:**

9 Youngsuk Ko¹, Yubin Seo³, Jin Ju Park³, Eun Jung Kim⁴, Jong Youn Moon⁵, Tark Kim⁶, Joong Sik
10 Eom⁷, Hong Sang Oh⁸, Arim Kim⁹, Jin Yong Kim¹⁰, Jacob Lee^{3*}, and Eunok Jung^{2*}

11

12 ¹ Institute of Mathematical Sciences, Konkuk University, Seoul, Korea

13 ² Department of Mathematics, Konkuk University, Seoul, Korea

14 ³ Division of Infectious Disease, Department of Internal Medicine, Kangnam Sacred Heart Hospital, College of
15 Medicine, Hallym University, Seoul, Korea

16 ⁴ National Assembly Research Service, Seoul, Korea

17 ⁵ Department of preventive medicine, College of medicine, Gachon University, Incheon, Korea

18 ⁶ Division of Infectious Diseases, Soonchunhyang University Bucheon Hospital, Bucheon, Korea

19 ⁷ Division of Infectious Diseases, Department of Internal Medicine, Gil Medical Center, College of Medicine,
20 Gachon University, Incheon, Korea

21 ⁸ Division of Infectious Disease, Department of Internal Medicine, Hallym University Sacred Heart Hospital,
22 Gyeonggi-do, Korea

23 ⁹ Gachon Biomedical Convergence Institute, Gachon, Korea

24 ¹⁰ Division of Infectious Diseases, Department of Internal Medicine, Incheon Medical Center, Incheon, Korea

25 *Corresponding author

26

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

27 **Abstract**

28 Smallpox, caused by the variola virus, is one of the most devastating diseases in human history and
29 was eradicated through global vaccination efforts by 1980. Despite its eradication, the virus remains
30 in high-security laboratories for research purposes, posing the potential risk of bioterrorism. This
31 study developed a mathematical model to analyze potential smallpox epidemics by incorporating
32 factors such as age groups, heterogeneous contact patterns, and various intervention strategies
33 including contact tracing, ring vaccination, and mass vaccination. The model simulations indicated
34 that the Republic of Korea's current plans for negative-pressure isolation beds should suffice under
35 most scenarios, but extreme worst-case scenarios could overwhelm healthcare capacity. This study
36 highlights the critical importance of non-pharmaceutical interventions and strategic vaccination
37 prioritization for controlling outbreaks. These findings provide valuable guidance for public health
38 officials and policymakers in preparing for potential bioterrorism threats and emerging infectious
39 diseases. Furthermore, emphasizes the need for comprehensive preparedness and robust response
40 strategies. The proposed framework applies to smallpox and to other infectious diseases, offering
41 insights for future outbreak management.

42

43 **Abbreviations**

44 NPIs: Non-pharmaceutical interventions

45 PEP: Post-exposure prophylaxis

46 ROK: Republic of Korea

47 CrI: Credible interval

48 PRCC: Partial Rank Correlation Coefficient

49

50 **Introduction**

51 Smallpox, caused by the variola virus, is one of the most devastating diseases affecting humans(1).

52 With its origins traced back to ancient civilizations, smallpox has spread across continents. The

53 disease is characterized by a high fever, severe skin eruptions, and a significant fatality rate

54 (approximately 30%), making it a formidable threat to populations worldwide.

55 The pioneering findings of Jenner and concerted global efforts, including mass vaccination

56 campaigns, surveillance, and implementation of ring vaccination strategies, led to the gradual decline

57 of smallpox cases. Non-pharmaceutical interventions (NPIs), such as disease surveillance, case

58 finding, and contact tracing, are also crucial for containing the spread of the virus(2). Ring

59 vaccination involves vaccinating all individuals near a detected case to prevent the spread of the virus.

60 Additionally, post-exposure prophylaxis (PEP) has been used to vaccinate individuals exposed to the

61 virus, further preventing outbreaks(3,4). The World Health Organization (WHO) launched an

62 intensified eradication program in 1967, which culminated in the declaration of smallpox eradication

63 in 1980.

64 Despite its eradication, the variola virus remains in two high-security laboratories: the Centers for

65 Disease Control and Prevention in the United States and the State Research Center of Virology and

66 Biotechnology in Russia(5). The virus is retained for research purposes, including developing new

67 vaccines and treatments. However, the presence of these viral stocks poses the potential risk of

68 bioterrorism. Given the lack of widespread immunity in the current global population, the deliberate

69 release of the smallpox virus could lead to a catastrophic outbreak. Two notable laboratory-related

70 smallpox incidents underscored the importance of maintaining vigilance. In 1971, the Aral Smallpox

71 incident in Soviet Russia led to ten infections and three deaths(6). Similarly, in 1978, a laboratory

72 accident in Birmingham, England resulted in two infections and one death(7).

73 A notable scenario that underscores the potential threat of smallpox as a bioterrorism agent is Dark

74 Winter exercises (8). This senior-level bioterrorist attack simulation depicted a covert smallpox attack

75 in the United States starting in Oklahoma City and rapidly spreading to other states. The exercise

76 revealed significant gaps in the national emergency response, highlighting the challenges of

77 containing the outbreak, managing public panic, and maintaining essential services. Winter's findings
78 emphasize the need for robust preparedness plans, including sufficient vaccine stockpiles, effective
79 communication strategies, and coordinated efforts between public health and security agencies, to
80 mitigate the impact of such a bioterrorism event.

81 Mathematical models are crucial in understanding and controlling infectious disease outbreaks,
82 including smallpox, as demonstrated in various studies. Ferguson emphasized the effectiveness of
83 targeted surveillance and containment interventions such as ring vaccination in controlling smallpox
84 outbreaks, underscoring the need for a rapid response (9). Meltzer constructed a model to evaluate
85 quarantine and vaccination interventions after a bioterrorist attack and demonstrated that a
86 combination of these strategies was effective in halting disease transmission (10). Ohushima
87 developed a model to predict smallpox outbreaks in Japan, evaluated the control measures, and found
88 that mass vaccination was more effective than ring vaccination under certain conditions (11). Chun
89 used epidemic modeling and tabletop exercises to prepare public health officials in the ROK for
90 potential outbreaks, highlighting the importance of these tools in estimating cases, deaths, and
91 resource shortages (12).

92 In this study, we developed a mathematical model to analyze potential smallpox epidemics by
93 incorporating various realistic factors such as age groups and heterogeneous contact patterns. The
94 model includes contact tracing, ring vaccination, and mass vaccination strategies and distinguishes
95 severe cases among infected individuals to discuss the required capacity for severe patients in
96 emergency scenarios. The insights gained from vaccination prioritization during the COVID-19
97 pandemic were also analyzed in relation to potential smallpox scenarios. Given the threat of smallpox
98 as a bioterrorism agent, this study evaluated reactive intervention protocols by simulating various
99 outbreak scenarios and assessing the effectiveness of NPIs, vaccination strategies, and isolation
100 facilities. These findings highlight the importance of early detection, rapid response, and strategic
101 vaccination prioritization. The proposed framework addresses smallpox and offers insights applicable
102 to other emerging infectious diseases, emphasizing the need for comprehensive preparedness in the
103 face of potential bioterrorism threats.

104 **Materials and Methods**

105 **Mathematical modeling of smallpox epidemic**

106 To investigate the transmission dynamics of potential smallpox epidemics, we developed a
107 susceptible-infectious-recovered-type mathematical model that reflects contact tracing, disease
108 severity, age group, and ring/mass vaccination. The mathematical model is shown as a flow diagram
109 in Figure 1. Age groups are denoted by subscript (i) for each variable, and vaccinated individuals are
110 denoted by superscript (v). In this study, we categorized the population into 16 age groups, each
111 spanning 5 years, ranging from 0–4 years to 65 years and older in the Republic of Korea (13).

112

113

114

115 Figure 1. Flow diagram of the mathematical model of the smallpox epidemic.

116

117 In general, Susceptible-Infectious-Recovered type models have the transmission rate, typically
118 denoted by the symbol β , which consists of the contact rate per unit time (c) and the probability of
119 successful disease transmission (p), that is, $\beta = pc$. In this study, we distinguished between those
120 who had contact with infectious hosts but were not infected (C_i) and those who were infected after
121 contact (E_i). We also considered both close contact (λ_i^A) and social contact (λ_i^B). Close contacts were
122 incorporated based on a study by Prem et al.(14). Social contacts were assumed to be four times the
123 number of contacts, excluding household contacts. The probability of successful disease transmission
124 through close contact was set to 60%(15). Using this value and the next-generation matrix method, the
125 basic reproductive number through close contact was calculated to be approximately four (16).
126 Considering that the recorded basic reproductive number of smallpox is approximately six, the
127 probability of successful disease transmission through casual contact was set at 10%(17).
128 To incorporate contact tracing regardless of infection status, we used the symbol (q) to represent the
129 proportion of contact-traced individuals. Those who were traced after contact and those who were not
130 traced were distinguished using a tilde symbol (\sim). Here, casual contact was not traced. The infection
131 transmission periods for traced and non-traced individuals were set based on the time from symptom
132 onset to isolation during the COVID-19 pandemic in the ROK (18). We assumed that contact-traced
133 individuals would be hospitalized/isolated relatively quickly (within 2.3 days, $1/\alpha$) after symptom
134 onset, while non-traced individuals would be isolated after 6.8 days ($1/\tilde{\alpha}$), considering the time to the
135 appearance of definitive smallpox symptoms (lesions)(19). The severity rate in the model (z_i) was set
136 to twice the infection fatality ratio. Thus, in the model simulations, half of the severe patients died,
137 whereas there were no deaths among non-severe patients.
138 Vaccination was applied in two forms in the model: mass vaccination (μ_m) and ring vaccination (μ_r).
139 Ring vaccination was prioritized and administered after case isolation but not in those who had
140 already developed symptoms. Patients exposed to the infection either recovered or continued to show
141 symptoms depending on the effectiveness of PEP (e_{PEP}). Even those who did not directly receive the
142 effects of PEP experienced a reduction in severity/fatality rates due to partial effects. Mass
143 vaccination was administered to the entire population outside the ring vaccination targets, and those

144 who had already been vaccinated were not revaccinated even if they were contact-traced. Those who
 145 were isolated without infection or ring vaccination were discharged 19 days ($1/l$) after isolation(20).
 146 In response to the smallpox epidemic, we assumed that vaccinating 40 million people (approximately
 147 80% of the population) would be necessary to achieve herd immunity. Vaccination can be slow
 148 initially owing to the lack of available personnel who are educated and vaccinated. In the ROK, there
 149 was a small-scale vaccination for healthcare workers during the global Mpox outbreak in 2022 in
 150 response to the domestic influx (21). These individuals would be the first to start vaccination during a
 151 smallpox epidemic and could vaccinate other healthcare workers and target populations. Thus, we
 152 assumed the daily vaccination capacity follows a logistic growth model, considering the maximum
 153 daily vaccination capacity during the COVID-19 pandemic, set at 1 million (μ_{ub}). The vaccination
 154 process started with 1,000 vaccinations per day, with a logistic growth rate (r_v) of 0.1, and all 40
 155 million people were vaccinated after 110 days.

156 The model is formulated using ordinary differential equations as follows:

$$157 \quad \frac{dS_i}{dt} = -(\lambda_i^A + \lambda_i^B)S_i - \mu_m(S), \quad \frac{dS_i^v}{dt} = \mu_m(S) + \mu_m(\tilde{C}_i) + \mu_r(Q_i^s) + lQ_i^{sv} - (\lambda_i^A + \lambda_i^B)S_i^v,$$

$$158 \quad \frac{d\tilde{C}_i}{dt} = (1 - p^A)(1 - q)\lambda_i^A(S_i + \tilde{C}_i) + (1 - p^B)\lambda_i^B(S_i + \tilde{C}_i) - (\lambda_i^A + \lambda_i^B)\tilde{C}_i - \mu_m(\tilde{C}_i),$$

$$159 \quad \frac{dC_i}{dt} = (1 - p^A)q\lambda_i^A(S_i + \tilde{C}_i) + (1 - p^A)\lambda_i^A C_i + (1 - p^B)\lambda_i^B C_i - (\lambda_i^A + \lambda_i^B)C_i - \sigma C_i,$$

$$160 \quad \frac{d\tilde{C}_i^v}{dt} = (1 - p_v^A)(1 - q)\lambda_i^A(S_i^v + \tilde{C}_i^v) + (1 - p_v^B)\lambda_i^B(S_i^v + \tilde{C}_i^v) - (\lambda_i^A + \lambda_i^B)\tilde{C}_i^v,$$

$$161 \quad \frac{dC_i^v}{dt} = (1 - p_v^A)q\lambda_i^A(S_i^v + \tilde{C}_i^v) + (1 - p_v^A)\lambda_i^A C_i^v + (1 - p_v^B)\lambda_i^B C_i^v - (\lambda_i^A + \lambda_i^B)C_i^v - \sigma C_i^v,$$

$$162 \quad \frac{d\tilde{E}_i}{dt} = p^A(1 - q)\lambda_i^A(S_i + \tilde{C}_i) + p^B\lambda_i^B(S_i + \tilde{C}_i) - \kappa\tilde{E}_i - \mu_m(\tilde{E}_i),$$

$$163 \quad \frac{dE_i}{dt} = p^Aq\lambda_i^A(S_i + \tilde{C}_i) + p^A\lambda_i^A C_i + p^B\lambda_i^B C_i - \kappa E_i - \sigma E_i,$$

$$164 \quad \frac{d\tilde{E}_i^v}{dt} = (1 - e_{pep})\mu_m(\tilde{E}_i) + p_v^A(1 - q)\lambda_i^A(S_i^v + \tilde{C}_i^v) + p_v^B\lambda_i^B(S_i^v + \tilde{C}_i^v) - \kappa\tilde{E}_i^v,$$

$$165 \quad \frac{dE_i^v}{dt} = p_v^A q \lambda_i^A (S_i^v + \tilde{C}_i^v) + p_v^A \lambda_i^A C_i^v + p_v^B \lambda_i^B C_i^v - \kappa E_i^v - \sigma E_i^v ,$$

$$166 \quad \frac{d\tilde{I}_i}{dt} = \kappa \tilde{E}_i - \tilde{\alpha} \tilde{I}_i , \quad \frac{dI_i}{dt} = \kappa E_i - \alpha I_i ,$$

$$167 \quad \frac{d\tilde{I}_i^v}{dt} = \kappa \tilde{E}_i^v - \tilde{\alpha} \tilde{I}_i^v , \quad \frac{dI_i^v}{dt} = \kappa E_i^v - \alpha I_i^v ,$$

$$168 \quad \frac{dQ_i^s}{dt} = \sigma C_i - \mu_r(Q_i^s) , \quad \frac{dQ_i^{sv}}{dt} = \sigma C_i^v - l Q_i^{sv} , \quad \frac{dQ_i^e}{dt} = \sigma E_i - \mu_r(Q_i^e) ,$$

$$169 \quad \frac{dQ_i}{dt} = (1 - z_i)(\tilde{\alpha} \tilde{I}_i + \alpha I_i) - \gamma_Q Q_i ,$$

$$170 \quad \frac{dQ_i^v}{dt} = (1 - z_i^v)((1 - e_{PEP})\mu_r(Q_i^e) + \tilde{\alpha} \tilde{I}_i^v + \alpha I_i^v + \sigma E_i^v) - \gamma_Q Q_i^v ,$$

$$171 \quad \frac{dH_i}{dt} = z_i(\tilde{\alpha} \tilde{I}_i + \alpha I_i) - \gamma_H H_i ,$$

$$172 \quad \frac{dH_i^v}{dt} = z_i^v((1 - e_{PEP})\mu_r(Q_i^e) + \tilde{\alpha} \tilde{I}_i^v + \alpha I_i^v + \sigma E_i^v) - \gamma_H H_i^v ,$$

$$173 \quad \frac{dR}{dt} = e_{PEP}(\mu_m(\tilde{E}_i) + \mu_r(Q_i^e)) + \gamma_Q(Q_i + Q_i^v) + (1 - f)\gamma_H(H_i + H_i^v) ,$$

$$174 \quad \lambda_i^A = \sum_j \frac{c_{ij}^A(I_j + I_j^v + \tilde{I}_j + \tilde{I}_j^v)}{N} , \quad \lambda_i^B = \sum_j \frac{c_{ij}^B(I_j + I_j^v + \tilde{I}_j + \tilde{I}_j^v)}{N} ,$$

$$175 \quad N = \sum_i S_i + S_i^v + \tilde{C}_i + C_i + \tilde{C}_i^v + C_i^v + \tilde{E}_i + E_i + \tilde{E}_i^v + E_i^v + \tilde{I}_i + I_i + \tilde{I}_i^v + I_i^v + R_i ,$$

$$176 \quad \mu(t) = \frac{\mu_{ub}}{1 + \exp(-r_v(t - t_0))} ,$$

$$177 \quad \mu_r^* = \min\left(\mu(t), \sum_i Q_i^s + Q_i^e\right) ,$$

$$178 \quad \mu_r(X) = \mu_r^* \frac{X}{\sum_i Q_i^s + Q_i^e} ,$$

$$179 \quad \mu_m(X) = (\mu(t) - \mu_r^*) \frac{X}{\sum_i S_i + \tilde{C}_i + \tilde{E}_i} .$$

180 The model parameters are listed in Table 1. As experienced during the COVID-19 pandemic, the scale
181 of the potential outbreaks remains uncertain. To reflect this, model simulations were conducted as a

182 stochastic process using the Tau-leaping method. We ran 1000 simulations for each model setting. As
183 an initial condition for the model simulation, all population groups were assumed to be in a
184 susceptible state. The number of exposed hosts was set to 100 and proportionally distributed
185 according to the population ratio of each group. Table 2 lists the population numbers in each group.
186

187 Table 1. Model parameters

Symbol	Description	Value	Reference
$1/\tilde{\alpha}$	Infectious period of contact-unidentified hosts	6.8 days	(18,19)
$1/\alpha$	Infectious period of contact-identified hosts	2.3 days	(18)
p_A	Probability of successful disease transmission per close contact	0.6	(15,16,18)
p_B	Probability of successful disease transmission per casual contact	0.1	(15,16,18)
q	Contact-identification ratio	0.8	Assumed
$1/l$	Isolation duration of uninfected case	19 days	(20)
$1/\sigma$	Contact tracing duration	2 days	Assumed
$1/\kappa$	Incubation period	12 days	(22)
$1/\gamma_Q$	Isolation duration of non-severe case	28 days	(22)
$1/\gamma_H$	Duration from hospitalization to recovery (or death) of severe case	13 days	(1)
z_i	Age dependent severity rate	0.83 (1) 0.47 (2,3) 0.61 (4,5) 0.59 (6-10) 0.64 (11-16)	(23)
f	Fatality rate of severe case	0.5	Assumed, (1)
e	Preventive vaccine effectiveness against infection	0.78	(24)
e_H	Vaccine effectiveness against severity	0.97	(24)
e_{pep}	Post-exposure prophylaxis vaccine effectiveness against infection	0.5	(25)

188

189 Table 2. Population size by age group

Age group	Age range	Population size
1	0-4 years	1455094
2	5-9 years	2151118
3	10-14 years	2368657
4	15-19 years	2330189
5	20-24 years	3011576
6	25-29 years	3501534
7	30-34 years	3278501
8	35-39 years	3362054
9	40-44 years	4047017
10	45-49 years	4075006
11	50-54 years	4543049
12	55-59 years	4102783
13	60-64 years	4185467
14	65-69 years	3118100
15	70-74 years	2192898
16	Age over 75 years	3835398

190

191 **Baseline model simulation scenario**

192 The simulation time was set as 365 days. The baseline model simulation scenario consisted of three
193 phases following the initial exposure:

- 194 ▶ Pre-declaration (Phase 1): This phase represents the period during which the occurrence of the
195 outbreak has not yet been recognized. No NPIs or vaccination measures were in place during
196 this phase, which lasted for 28 days after the initial exposure. This is the worst-case scenario,
197 set at a realistic level, considering the incubation period, initial symptoms, and occurrence of
198 rashes.
- 199 ▶ Post-declaration (Phase 2): This phase begins when the outbreak is first recognized, and
200 contact tracing and social distancing (NPIs) are implemented. However, vaccination is not yet
201 feasible because of the time required for preparation, e.g., training for medical personnel. This
202 phase lasted for three days. It was assumed that social distancing would reduce the total
203 contact rate by 60%.
- 204 ▶ Post-vaccination (Phase 3): This phase marks the beginning of vaccination. Vaccination
205 continued until 40 million people had been vaccinated. This phase lasted for 334 days.
206 Vaccination was administered simultaneously to all age groups, and the amount of vaccines
207 administered was proportional to the population of each group; that is, there was no vaccine
208 prioritization.

209
210 **Scenarios considering vaccine prioritization**

211 Vaccination was not prioritized in the baseline scenario considered in this study. However, as
212 experienced by most countries during the COVID-19 pandemic, prioritizing vaccination may be a
213 more realistic approach. We defined four criteria for the prioritization scenarios: ascending age,
214 descending age, prioritizing age groups with higher transmission risk, and prioritizing age groups with
215 higher severity/death risk. The age groups with higher transmission risk were calculated based on the
216 contact rate and the probability of successful disease transmission, and the order was as follows: age
217 groups 4 (15-19 year), 3 (10-14 year), 9 (40-44 year), 8 (35-39 year), 7 (30-34 year), 6 (25-29 year),

218 10 (45-49 year), 11 (50-54 year), 5 (20-24 year), 2 (5-9 year), 12 (55-59 year), 13 (60-64 year), 1 (0-4
219 year), 14 (65-69 year), 15 (70-74 year), 16 (75+ year).

220 **Results**

221 **Baseline scenario simulation**

222 Figure 2 shows the model simulation results for the confirmed cases (transition from infectious to
223 isolated) and isolated patients. The curves represent the mean values of the model simulations, and
224 shaded areas indicate the 95% credible interval (CrI). The red graph shows the daily confirmed cases,
225 whereas the blue curves represent isolated patients. Among the blue curves, the solid and dashed lines
226 indicate patients with non-severe and severe patients.

227 Daily confirmed cases increased sharply (mean 1167, maximum 1602 in 95% CrI) owing to contact
228 tracing implemented at the initial outbreak recognition, and then decreased, followed by a gradual
229 increase, and finally decreased again owing to herd immunity from vaccination. The number of non-
230 severe patients reached a mean of 3750 (maximum 5422 in 95% CrI) after 114 days of spread,
231 whereas that of severe patients reached a mean of 1235 (maximum 1838 in 95% CrI) after 99 days of
232 exposure.

233

234

235

236 Figure 2. Baseline scenario simulation results. Curves indicate mean simulation results and shaded
237 areas indicate the 95% credible interval.

238

239

240 The confirmed cases and deaths observed in the simulation runs are presented in Figure 3 using box-
241 and-whisker plots. Panels A and B show the confirmed cases, and panels C and D show the number of
242 deaths. The total number of confirmed cases was 36600 (95% CrI [24253, 51500]) and the total
243 number of deaths was 5345 (95% CrI [3472, 7545]). Age group 9 (40–44 years) had the highest
244 number of confirmed cases, with a mean of 4241 (95% CrI [2846, 5969]). Group 11 (50–54 years)
245 had the highest number of deaths, with a mean age of 677 years (95% CrI [447, 936]). The age group
246 0–4 years had the lowest number of confirmed cases (mean 361, 95% CrI 237, 513]) and deaths
247 (mean 68, 95% CrI [41, 101]).

248 In addition to the baseline scenario, the results for different initial numbers and logistic growth rates
249 for vaccinations and the varying effects of social distancing on contact reduction are listed in Tables
250 3–5.

251

252

253 Figure 3. Outbreak outcomes from the baseline scenario simulations: Distribution of the number of
254 confirmed cases by age (A) and total (B), deaths by age (C) and total (D).

255

256 Table 3. Mean and 95% CrI of outbreak outcomes with a 50% reduction in contacts due to social
257 distancing.

Initial vaccination number	Growth rate	Confirmed cases	Deaths	Peak severe patients
1000 (baseline)	0.05	260458 [170462, 354688]	34255 [22388, 46734]	7608 [4983, 10423]
	0.1 (baseline)	90947 [60018, 127048]	11890 [7842, 16516]	3182 [2080, 4452]
	0.5	29323 [19519, 40916]	3816 [2588, 5298]	1369 [909, 1915]
5000	0.05	144457 [94173, 199367]	19008 [12540, 25960]	4411 [2875, 6109]
	0.1 (baseline)	64585 [41862, 90666]	8451 [5588, 11793]	2381 [1562, 3349]
	0.5	26828 [17542, 37368]	3491 [2316, 4847]	1282 [849, 1796]
10000	0.05	111421 [73076, 157301]	14671 [9640, 20653]	3507 [2303, 4973]
	0.1 (baseline)	56267 [38326, 76475]	7358 [5030, 9959]	2135 [1458, 2922]
	0.5	26075 [17039, 37098]	3391 [2269, 4682]	1261 [819, 1759]

258

260 Table 4. Mean and 95% CrI of outbreak outcomes with a 60% reduction in contacts due to social
261 distancing.

Initial vaccination number	Growth rate	Confirmed cases	Deaths	Peak severe patients
1000 (baseline)	0.05	60356 [40271, 84492]	8894 [5950, 12436]	1475 [985, 2094]
	0.1 (baseline)	36886 [24398, 51467]	5391 [3581, 7513]	1281 [838, 1786]
	0.5	18611 [12524, 25865]	2676 [1827, 3706]	1048 [707, 1455]
5000	0.05	46071 [30001, 63246]	6784 [4461, 9343]	1318 [848, 1808]
	0.1 (baseline)	30803 [20538, 42278]	4495 [2996, 6173]	1208 [797, 1682]
	0.5	17614 [11806, 24104]	2530 [1713, 3410]	1028 [691, 1411]
10000	0.05	40645 [26835, 56652]	5981 [3918, 8371]	1261 [827, 1787]
	0.1 (baseline)	28100 [19317, 39537]	4098 [2792, 5702]	1168 [790, 1642]
	0.5	17103 [11403, 23652]	2457 [1669, 3365]	1012 [684, 1404]

262

263

264 Table 5. Mean and 95% CrI of outbreak outcomes with a 70% reduction in contacts due to social
 265 distancing.

Initial vaccination number	Growth rate	Confirmed cases	Deaths	Peak severe patients
1000 (baseline)	0.05	20749 [13713, 29494]	3370 [2225, 4805]	894 [602, 1256]
	0.1 (baseline)	17565 [11933, 23971]	2851 [1947, 3852]	881 [605, 1186]
	0.5	12510 [8588, 17000]	1985 [1358, 2681]	890 [611, 1224]
5000	0.05	19069 [13225, 26800]	3101 [2105, 4343]	891 [625, 1237]
	0.1 (baseline)	16446 [11093, 22420]	2663 [1853, 3608]	893 [596, 1228]
	0.5	12006 [8172, 16475]	1898 [1321, 2584]	884 [598, 1215]
10000	0.05	18288 [12598, 25139]	2975 [2042, 4084]	891 [625, 1210]
	0.1 (baseline)	15724 [11007, 21809]	2545 [1781, 3533]	889 [609, 1224]
	0.5	11900 [8028, 16371]	1879 [1285, 2577]	890 [596, 1228]

266

267

268 Figure 4 shows the distribution of hosts who had contact with infected individuals at outbreak
269 recognition 28 days after initial exposure. The average numbers of hosts who had contact (whether
270 they were infected or not), hosts during the incubation period, and hosts in the contagious stage were
271 5618 (95% CrI [3786, 7776]), 3401 (95% CrI [2288, 4706]), and 926 (95% CrI [623, 1275]),
272 respectively.

273

274

275

276 Figure 4. Distribution of the number of hosts who had hazardous contact until the outbreak
277 recognition in different stages.

278

279 Figure 5 shows the mean daily vaccination number (panel A), the distribution of administered ring
280 vaccinations in the simulation runs (panel B), and the ring vaccination period (panel C). In this study,
281 the ring vaccination period was considered the point at which the mass vaccination exceeded the
282 amount of ring vaccination. The average number of ring vaccinations administered was 28750 (95%
283 CrI [19145,40218]), and the vaccination period lasted an average of 5.53 days (95% CrI [3.5, 8]).

284

285

286

287 Figure 5. Vaccination number in the baseline scenario simulations: Mean daily vaccination number
288 (A), distribution of administered ring vaccination, and period (B,C).

289

290

291 **Impact of vaccine prioritization**

292 The simulation results, including the baseline scenario and scenarios with vaccine prioritization, are
293 shown in Figure 6. Panels A and B show the daily numbers of confirmed and severe cases,
294 respectively. Compared with the baseline scenario, prioritizing vaccination for age groups with a
295 higher transmission risk (purple) showed a decrease, whereas prioritizing vaccination for older age
296 groups (yellow) showed a significant increase. Table 5 lists the odds ratios for cumulative confirmed
297 cases, deaths, and the peak number of severe patients compared to the baseline scenario. When
298 prioritization based on transmissibility was applied, the odds ratios for all metrics were below one,
299 within the confidence interval. Conversely, when prioritization based on descending age was applied,
300 the odds ratios for all metrics exceeded one.

301

302

303

304 Figure 6. Simulation results considering vaccine prioritization: Daily confirmed cases (A),
305 administered to severe patients (B).

306

307 Table 6. Odds ratios and confidence intervals for scenarios considering vaccine prioritization
308 compared to the baseline scenario.

Vaccine prioritization	Confirmed cases	Deaths	Peak number of administered patients
Ascending age	0.97, [0.95 0.98]	0.98, [0.96 0.99]	1.02, [1.00 1.03]
Descending age	1.07, [1.06 1.09]	1.08, [1.06 1.09]	1.04, [1.02 1.06]
Transmissibility	0.89, [0.87 0.90]	0.90, [0.89 0.92]	0.96, [0.94 0.97]
Fatality	1.03, [1.02 1.05]	1.03, [1.01 1.05]	1.00, [0.98 1.01]

309

310

311 Sensitivity analysis

312 To address the inherent uncertainties in these values and conduct a comprehensive sensitivity analysis
313 of the model outcomes, we measured the partial rank correlation coefficient (PRCC) values using
314 Latin hypercube sampling. PRCC is a statistical measure used to determine the strength and direction
315 of the relationship between two variables while controlling for the effects of other variables. In
316 sensitivity analysis, it is particularly useful to identify the parameters that have the most significant
317 impact on the output of a model. A detailed description of this method is provided in reference (26).
318 We considered the following model inputs: outbreak recognition timing, impact of social distancing
319 on contact number, infectious period of traced and non-traced cases, contact identification ratio, and
320 logistic growth rate of the daily vaccination number. The model outputs were set as the cumulative
321 confirmed cases and deaths, and the peak number of administered severe patients.
322 Figure 7 shows the measured absolute values of PRCC over time. The colors in the graph represent
323 the model inputs. Solid curves indicate the values for cumulative confirmed cases, whereas solid
324 curves indicate the values for cumulative deaths. The order of the absolute PRCC values for the model
325 inputs was the same regardless of whether the model output was cumulative confirmed cases or
326 deaths. Based on the final absolute PRCC values, the timing of outbreak recognition had the highest
327 value, with 0.90 for cumulative confirmed cases and deaths. The contact identification ratio initially
328 had a relatively high absolute PRCC (0.29) for cumulative confirmed cases but decreased to 0.01,
329 resulting in the lowest PRCC. Table 7 lists the ranges of PRCC values. In contrast to Figure 7, the
330 absolute value of the PRCC for the growth rate of daily vaccination was the second smallest when the
331 considered model output peaked for severe patients. Additionally, outbreak recognition timing had the
332 highest absolute PRCC.

333

334

335 Figure 7. Absolute value of PRCC over time. Solid lines represent the value for cumulative confirmed
336 cases, while dashed lines represent the value for cumulative deaths.

337

338 Table 7. The final value and range of PRCC of model inputs considering different model outputs.
 339 There is no range if the target model output is the peak number of severe patients as there is a one-
 340 time point of it.

Model input	Model output		
	Cumulative confirmed cases	Cumulative deaths	Peak severe patients
Outbreak recognition timing	0.90 [0, 0.93]	0.90 [-0.19, 0.93]	0.88
Impact of social distancing	-0.93 [-0.93, 0.01]	-0.91 [-0.91, 0]	-0.85
Isolation rate for traced cases	-0.28 [-0.28, 0]	-0.32 [-0.32, 0.04]	-0.27
Isolation rate for non-traced cases	-0.89 [-0.89, -0.26]	-0.88 [-0.88, 0.2]	-0.81
Contact-identification ratio	-0.01 [-0.29, -0.01]	-0.01 [-0.01, 0.01]	-0.02
Growth rate of the daily vaccination	-0.31 [-0.31, 0]	-0.33 [-0.33, 0]	-0.16

341

342 **Discussion**

343 The model simulation showed a rapid increase in confirmed cases upon initial detection, followed by
344 a gradual increase in the number of severely ill patients. By 2024, the ROK plans to expand the
345 number of negative-pressure isolation beds to 3500 to respond to emerging infectious diseases(27).

346 According to the baseline scenario results, even in the worst case within the 95% CrI, the peak
347 administered to severely ill patients was 1800 (Figure 2), indicating that the current plan should
348 prevent a shortage of beds. However, in an extreme worst-case scenario, where the vaccination rate is
349 low and the impact of social distancing is weak (upper row in Table 3), the number of administered
350 severe cases could reach up to 7600, posing a significant risk. However, if the effectiveness of social
351 distancing reaches at least 0.6, dangerous situations are avoided. Therefore, the results suggest that a
352 minimum level of NPIs required during a smallpox outbreak. This level was measured to be near the
353 level of social distancing stage 2 in previous COVID-19 studies and is not an unrealistic measure in a
354 bioterrorism situation where nationwide interventions would be stricter.

355 The parameter sensitivity analysis results provided additional support for the basic model simulation
356 outcomes. The analysis revealed that both deaths and confirmed cases were highly sensitive to
357 recognition timing, impact of social distancing, and isolation rate for non-traced cases (Figure 7 and
358 Table 7). This underscores the significant role of NPIs in achieving herd immunity through
359 vaccination.

360 The distribution of hosts with contagious contacts at the initial outbreak recognition (Figure 4)
361 represents the minimum number of ring vaccination targets that need to be considered immediately.
362 Considering the additional real-time increase in the number of contacts and exposed individuals, the
363 distribution shown in Figure 5 indicates the overall scope of the ring vaccination plan. Although these
364 individuals represented a small proportion (approximately 0.1%) of the total vaccination scale, ring
365 vaccination was primarily conducted during the first week of the initial vaccination period. Our
366 findings serve as a basis for determining the operation and number of distribution points during this
367 period.

368 Determining vaccine priorities is challenging because of various social, economic, and ethical issues.

369 Similar problems have been encountered during the COVID-19 pandemic. Prioritizing vaccination for
370 the elderly, who have higher severity/fatality rates, was the best strategy for minimizing deaths when
371 social distancing measures were in place to reduce the effective reproduction number to
372 approximately one (28,29). However, if the effective reproduction number increases, prioritizing the
373 elderly would be less effective than vaccinating younger adults in minimizing deaths. The study was
374 based on the original strain of COVID-19, which had a basic reproductive number of approximately
375 three, roughly half of that of smallpox. This implies that strong NPIs can effectively suppress the
376 spread. Conversely, for smallpox, for which moderate levels of NPIs were not sufficient to control the
377 spread, prioritizing vaccination for groups with higher transmission rates was more effective in
378 reducing deaths. Prioritizing the elderly yielded the least favorable results. If the vaccination history
379 of the elderly, which was not considered in this study, were accounted for, they would likely have a
380 relatively lower severity/fatality rate compared to other age groups, further diminishing the
381 effectiveness of the first vaccination strategy.

382 The limitations of this study are as follows. For social contacts, we only used estimates based on close
383 contacts. Age-specific severity rates were derived from data that included both vaccinated and
384 unvaccinated individuals, which may differ from the actual values. We did consider the smallpox
385 vaccinations administered in the ROK until the early 1970s and rather assumed that all population
386 groups were susceptible. However, despite the lack of vaccine effectiveness against infection, the
387 elderly might have a lower severe/fatality rate than other age groups due to their vaccination history.
388 Finally, although the smallpox vaccine can have significant side effects, we did not incorporate these
389 side effects into our model. This was because vaccination coverage was fixed. Future studies will
390 focus on analyzing optimal vaccination strategies, taking into account side effects, spatial
391 heterogeneity, and regional lockdowns.

392 **Conclusion**

393 Based on the findings of this study and considering realistic intervention scenarios and outbreak
394 situations, we propose an appropriate number of isolation facilities for severely ill patients and the
395 necessary level of initial social distancing. Various simulations have highlighted the critical
396 importance of early detection and rapid responses to mitigate the impact of smallpox outbreaks. These
397 results underscore the need for robust preparedness plans that include vaccination and NPIs.
398 Our study emphasizes the importance of strategic vaccination prioritization and the role of NPIs in
399 controlling outbreaks. The insights gained from this study provide valuable guidance to public health
400 officials and policymakers in preparing for and responding to potential bioterrorism threats and
401 emerging infectious diseases. The critical importance of early detection, rapid response, and
402 comprehensive preparedness cannot be overstated when safeguarding public health.
403 The overall framework of this study applies to smallpox and other emerging infectious diseases that
404 may spread to humans in the future. By incorporating parameters similar to those applied in this
405 study, response strategy scenarios can be developed for diseases that can be controlled using currently
406 available vaccines. Conversely, for novel diseases with significant time requirements for vaccine
407 development, this framework can be adapted to simulate the post-declaration phase responses.
408

409 **Acknowledgement**

410 This research was supported by the Government-wide R&D Fund Project for Infectious Disease
411 Research (GFID), Republic of Korea (grant No. HG23C1629). This work was supported by the
412 Research Program funded by the Korea Disease Control and Prevention Agency (정책, 150).
413

414 **Reference**

- 415 1. Fenner F, Henderson DA, Arita I, Ježek Z, Ladnyi ID. Smallpox and its eradication continued.
416 1988.
- 417 2. Henderson DA. Principles and lessons from the smallpox eradication programme. Bull World
418 Health Organ. 1987;65(4):535.
- 419 3. Kretzschmar M, Van den Hof S, Wallinga J, Van Wijngaarden J. Ring vaccination and
420 smallpox control. Emerg Infect Dis. 2004;10(5):832.
- 421 4. Keckler MS, Reynolds MG, Damon IK, Karem KL. The effects of post-exposure smallpox
422 vaccination on clinical disease presentation: addressing the data gaps between historical
423 epidemiology and modern surrogate model data. Vaccine. 2013;31(45):5192–201.
- 424 5. Tucker JB. Breaking the deadlock over destruction of the smallpox virus stocks. Biosecur
425 Bioterror. 2011;9(1):55–67.
- 426 6. Zelicoff AP. An epidemiological analysis of the 1971 smallpox outbreak in Aralsk,
427 Kazakhstan. Crit Rev Microbiol. 2003;29(2):97–108.
- 428 7. Harling R, Morgan D, Edmunds WJ, Campbell H. Interim smallpox guidelines for the United
429 Kingdom: Developing new policies from old evidence. Vol. 325, BMJ. British Medical
430 Journal Publishing Group; 2002. p. 1371–2.
- 431 8. O’Toole T, Mair M, Inglesby T V. Shining light on " Dark Winter". Clinical Infectious
432 Diseases. 2002;972–83.
- 433 9. Ferguson NM, Keeling MJ, John Edmunds W, Gani R, Grenfell BT, Anderson RM, et al.
434 Planning for smallpox outbreaks. Nature. 2003;425(6959):681–5.
- 435 10. Meltzer MI, Damon I, LeDuc JW, Millar JD. Modeling potential responses to smallpox as a
436 bioterrorist weapon. Emerg Infect Dis. 2001;7(6):959.
- 437 11. Ohkusa Y, Taniguchi K, Okubo I. Prediction of smallpox outbreak and evaluation of control-
438 measure policy in Japan, using a mathematical model. Journal of Infection and Chemotherapy.
439 2005;11(2):71–80.
- 440 12. Chun BC. Epidemic modeling and Table-top Exercise for Emerging Infectious Diseases in
441 Korea. Epidemiol Health. 2006;28(1):47–63.
- 442 13. Ministry of the Interior and Safety. Population Status by Age and Administrative District
443 [Internet]. [cited 2024 Sep 23]. Available from: <https://jumin.mois.go.kr/ageStatMonth.do>
- 444 14. Prem K, Cook AR, Jit M. Projecting social contact matrices in 152 countries using contact
445 surveys and demographic data. PLoS Comput Biol. 2017;13(9):e1005697.
- 446 15. Centers for Disease Control and Prevention. Smallpox-Transmission [Internet]. [cited 2024
447 Sep 23]. Available from: <https://www.cdc.gov/smallpox/transmission/index.html>
- 448 16. Diekmann O, Heesterbeek JAP, Roberts MG. The construction of next-generation matrices for
449 compartmental epidemic models. J R Soc Interface. 2010;7(47):873–85.
- 450 17. Gani R, Leach S. Transmission potential of smallpox in contemporary populations. Nature.
451 2001;414(6865):748–51.
- 452 18. Shim E, Choi W, Song Y. Clinical time delay distributions of COVID-19 in 2020–2022 in the
453 Republic of Korea: inferences from a nationwide database analysis. J Clin Med.
454 2022;11(12):3269.

- 455 19. G. Bras. *The Morbid Anatomy of Smallpox*. 4th ed. Vol. 4. *Documenta de Medicina*
456 *Geographica et Tropica*; 1952. 303–351 p.
- 457 20. Korea Disease Control and Prevention Agency. *Guidelines for Responding to Class 1*
458 *Infectious Diseases* [Internet]. 2024 [cited 2024 Sep 23]. Available from:
459 <https://www.kdca.go.kr/contents.es?mid=a20301110100>
- 460 21. Yonhap News Agency. *First vaccination of medical staff against monkeypox... Vaccination is*
461 *tricky* [Internet]. [cited 2024 Sep 23]. Available from:
462 <https://www.yna.co.kr/view/MYH20220627014500641>
- 463 22. Centers for Disease Control and Prevention. *Smallpox-symptoms* [Internet]. [cited 2024 Sep
464 23]. Available from: <https://www.cdc.gov/smallpox/symptoms/index.html>
- 465 23. Mazumder DNG, De S, Mitra AC, Mukherjee MK. *Clinical observations on smallpox: a study*
466 *of 1233 patients admitted to the Infectious Diseases Hospital, Calcutta, during 1973*. *Bull*
467 *World Health Organ*. 1975;52(3):301.
- 468 24. Eichner M. *Analysis of historical data suggests long-lasting protective effects of smallpox*
469 *vaccination*. *Am J Epidemiol*. 2003;158(8):717–23.
- 470 25. Mohanty B, Costantino V, Narain J, Chughtai AA, Das A, MacIntyre CR. *Modelling the*
471 *impact of a smallpox attack in India and influence of disease control measures*. *BMJ Open*.
472 2020;10(12):e038480.
- 473 26. Helton JC, Davis FJ. *Latin hypercube sampling and the propagation of uncertainty in analyses*
474 *of complex systems*. *Reliab Eng Syst Saf*. 2003;81(1):23–69.
- 475 27. Korea Disease Control and Prevention Agency. [May 11th, Thursday, Regular Briefing Press
476 Release] *Promoting the Return to Normal Life from the COVID-19 Crisis* [Internet]. [cited
477 2024 Sep 23]. Available from:
478 [https://www.kdca.go.kr/board/board.es?mid=a20501010000&bid=0015&list_no=722503&cg_](https://www.kdca.go.kr/board/board.es?mid=a20501010000&bid=0015&list_no=722503&cg_code=&act=view&nPage=1)
479 [code=&act=view&nPage=1](https://www.kdca.go.kr/board/board.es?mid=a20501010000&bid=0015&list_no=722503&cg_code=&act=view&nPage=1)
- 480 28. Bubar KM, Reinholt K, Kissler SM, Lipsitch M, Cobey S, Grad YH, et al. *Model-informed*
481 *COVID-19 vaccine prioritization strategies by age and serostatus*. *Science* (1979).
482 2021;371(6352):916–21.
- 483 29. Ko Y, Lee J, Kim Y, Kwon D, Jung E. *COVID-19 vaccine priority strategy using a*
484 *heterogenous transmission model based on maximum likelihood estimation in the Republic of*
485 *Korea*. *Int J Environ Res Public Health*. 2021;18(12):6469.
- 486




Figure 4






Figure 5




Figure 6




Figure 7




Figure 1




Figure 2




Figure 3